Zobrazeno 1 - 10
of 40
pro vyhledávání: '"James Cleary"'
Autor:
Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, Osama Rahma, F Stephen Hodi, Kevin Tyan, Joanna Baginska, Martha Brainard, James Cleary, Benjamin Schlechter, Anna Maloney, Rizwan Romee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/bb13f9b6739d4ca29f20d134aa05013b
Autor:
James Cleary
Publikováno v:
The Pursuit of Life ISBN: 9780271094922
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84833599900957dc830aea9e86bd07a7
https://doi.org/10.1515/9780271094922-013
https://doi.org/10.1515/9780271094922-013
Autor:
James Harding, Sarina Piha-Paul, Ronak Shah, Jessica Murphy, James Cleary, Geoffrey Shapiro, David Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James Ford, Monica Arnedos, Salomon Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael Berger, Lisa Eli, Funda Meric-Bernstam, Komal Jhaveri, David Solit, Ghassan K Abou-Alfa
HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b700187bbc235ce424c878694ad5b456
https://doi.org/10.21203/rs.3.rs-1576467/v1
https://doi.org/10.21203/rs.3.rs-1576467/v1
Autor:
Kristine L. Kwekkeboom, Ronald C. Serlin, Sandra E. Ward, Thomas W. LeBlanc, Adeboye Ogunseitan, James Cleary
Publikováno v:
Pain. 163(3)
Autor:
Diederik Lohman, James Cleary, Stephen Connor, Liliana De Lima, Julia Downing, Joan Marston, Claire Morris, Sara Pardy, Katherine Pettus
Publikováno v:
Journal of pain and symptom management. 64(1)
Between 2000 and 2020 Open Society Foundations was one of very few funders that supported global palliative care development and advocacy.To describe progress made in three priority areas-the integration of palliative care into public health systems,
Autor:
Michael Cecchini, Joseph Chao, Yu Shyr, James Cleary, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristin Spencer, Edward Kim, Chih-Yuan Hsu, Stacey Stein, Jaykumar Thumar, Jeremy Kortmansky, John Kunstman, Patricia LoRusso, Percy Ivy, Jill Lacy
Publikováno v:
Cancer Research. 82:CT170-CT170
Background: Ramucirumab is a monoclonal antibody that binds to the vascular endothelial growth factor receptor 2, increasing hypoxia in the tumor microenvironment. In advanced gastric cancer, single agent ramucirumab is well tolerated and improves ov
Autor:
Howgate, James Cleary
About one in five children aged 5 to 11 years have at least one untreated, decayed tooth (Dye, Li, & Beltran-Aguilar, 2012) and tooth decay is the number one chronic disease in children (S. O. Griffin, Wei, Gooch, Weno, & Espinoza, 2016). More than 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f9e54aa35c8b726bc27fe2ef532a96a
Autor:
James Cleary
Publikováno v:
Reading and the First World War ISBN: 9781349570591
In his introduction to Eric Partridge’s little-known classic of the First World War, Frank Honywood, Private, Geoffrey Serle comments: the First AIF [Australian Imperial Force], a volunteer citizen’s army as no other was, was made up of a near cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab69d23907d24a7ca392ca1ad24223be
https://doi.org/10.1057/9781137302717.0016
https://doi.org/10.1057/9781137302717.0016
Autor:
Florian Strasser, Mark P. Jensen, Stein Kaasa, Tarja Heiskanen, John T. Farrar, Oscar Corli, Nan E. Rothrock, Catherine Deguines, G. Apolone, Pål Klepstad, Massimo Costantini, Mogens Groenvold, Marianne Jensen Hjermstad, Robin L. Fainsinger, J. H. Loge, James Cleary, Vittorina Zagonel, Henry J. McQuay, Augusto Caraceni
Publikováno v:
BMJ supportivepalliative care. 1(3)
An increasing number of cancer patients live longer, and palliative care has become an important part of their treatment. Symptoms are often inadequately assessed and managed. A significant challenge in clinical trials is to control for the variabili